|
HER-2/neu Pos |
|
Wyeth 3144A2-3004- |
A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer |
|
Hormone Receptor Pos |
|
NSABP B-42 |
5yrs of Letrozole vs Placebo after Completing 5yrs of Hormonal Tx with an AI or Tamoxifen Followed by an AI in Prolonging DFS in Postmenopausal Hormone Receptor Positive BCA |
|
Node Pos/High Risk Node Neg |
|
ECOG 5103 |
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in LN+ and High Risk LN- Breast Cancer |
|
Oncotype Dx |
|
ECOG PACCT-1 |
Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trail (PACCT-1) |
|
COLORECTAL |
|
Metastatic, Second-Line |
|
Sanofi-Aventis EFC10262 |
A Randomized, Double-blind Study Comparing Efficacy of Aflibercept Once Every 2 Weeks vs Placebo in MCRC Treated with FOLFIRI after failure of an Oxaliplatin Regimen (VELOUR) |
|
Operable, Neoadjuvant |
|
NSABP R-04 |
Preoperative XRT and Capecitabine w/wo Oxaliplatin with Preoperative XRT and Continuous IV Infusion of 5-FU w/wo Oxaliplatin in Operable Carcinoma of the Rectum |
|
LUNG NON-SMALL CELL |
|
Stage IB-IIIA, Adjuvant |
|
ECOG 1505 |
Phase III Randomized Trial of Adjuvant Chemo w/wo Bevacizumab for Patients With Completely Resected Stage IB (³ 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC) |
|
Stage IIIB/IV or Recurrent, Second Line |
|
Boehringer Ingelheim |
Randomized, D-blind, PIII trial of oral BIBF1120 w Alimta vs placebo w Alimta in 2nd line stage IIIB/IV or recurrent NSCLC |
|
MELANOMA |
|
Microscopic |
|
ECOG 1697 |
Phase III Randomized 4 wks HD IFN-a2b in Stage in microscopic Melanoma |
|
MAGE-A3 Pos, Stage III |
|
GSK DERMA |
A Double-blind, Randomized, placebo-controlled PIII study of recMAGE-A3 + AS15 ASCI as Adjuvant Tx in MAGE-A3+ resected StgIII melanoma
|
|
Recurrent Metastatic |
|
Vical |
PIII Trial of Intralesional Allovectin-7® vs DTIC or TMZ in Recurrent Metastatic Melanoma |
|
RENAL |
|
Adjuvant |
|
ECOG 2805 |
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma |
|
Advanced |
|
ECOG 2804 |
The BeST Trial: A Randomized PII Study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced RCC |